Literature DB >> 25002377

Combining radiofrequency ablation and ethanol injection may achieve comparable long-term outcomes in larger hepatocellular carcinoma (3.1-4 cm) and in high-risk locations.

Ji-Wei Lin1, Chen-Chun Lin1, Wei-Ting Chen1, Shi-Ming Lin2.   

Abstract

Radiofrequency ablation (RFA) is more effective for hepatocellular carcinoma (HCC) < 3 cm. Combining percutaneous ethanol injection and RFA for HCC can increase ablation; however, the long-term outcome remains unknown. The aim of this study was to compare long-term outcomes between patients with HCC of 2-3 cm versus 3.1-4 cm and in high-risk versus non-high-risk locations after combination therapy. The primary endpoint was overall survival and the secondary endpoint was local tumor progression (LTP). Fifty-four consecutive patients with 72 tumors were enrolled. Twenty-two (30.6%) tumors and 60 (83.3%) tumors were of 3.1-4 cm and in high-risk locations, respectively. Primary technique effectiveness was comparable between HCC of 2-3 cm versus 3.1-4 cm (98% vs. 95.5%, p = 0.521), and HCC in non-high risk and high-risk locations (100% vs. 96.7%, p = 1.000). The cumulative survival rates at 1 year, 3 years, and 5 years were 90.3%, 78.9%, and 60.3%, respectively, in patients with HCC of 2-3 cm; 95.0%, 84.4%, and 69.3% in HCC of 3.1-4.0 cm (p = 0.397); 90.0%, 71.1%, and 71.1% in patients with HCC in non-high-risk locations; and 92.7%, 81.6%, and 65.4% in high-risk locations (p = 0.979). The cumulative LTP rates at 1 year, 3 years, and 5 years were 10.2%, 32.6%, and 32.6%, respectively, in all HCCs; 12.6%, 33.9%, and 33.9% in HCC of 2-3 cm; 4.8%, 29.5%, and 29.5% in HCC of 3.1-4 cm (p = 0.616); 16.7%, 50.0%, and 50.0% in patients with HCC in non-high-risk locations; and 8.8%, 29.9%, and 29.9% in patients with HCC in high-risk locations (p = 0.283). The cumulative survival and LTP rates were not significantly different among the various subgroups. Combining RFA and percutaneous ethanol injection achieved comparable long-term outcomes in HCCs of 2-3 cm versus 3.1-4.0 cm and in high-risk versus non-high-risk locations. A randomized controlled or cohort studies with larger sample size are warranted.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Hepatocellular carcinoma; High-risk locations; Percutaneous ethanol injection; Radiofrequency ablation

Mesh:

Substances:

Year:  2014        PMID: 25002377     DOI: 10.1016/j.kjms.2014.04.006

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  4 in total

Review 1.  Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.

Authors:  Lumin Chen; Jihong Sun; Xiaoming Yang
Journal:  Cancer Lett       Date:  2015-10-22       Impact factor: 8.679

2.  CT-guided percutaneous chemical ablation combined with radiofrequency ablation for hepatocellular carcinomas in high-risk locations: lobaplatin vs. ethanol.

Authors:  Wen-Dong Li; Xiao-Yan Ding; Wei Sun; Xiao-Di Guo; Sha-Sha Sun; Yan-Jun Shen; Li Li; Wei Li; Jing-Long Chen
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

3.  Comparison of radiofrequency ablation alone & in combination with percutaneous ethanol injection for management of hepatocellular carcinoma.

Authors:  Naveen Kalra; Mandeep Kang; Ajay K Duseja; Anmol Bhatia; Virendra Singh; Radha K Dhiman; Arvind Rajwanshi; Yogesh K Chawla; Niranjan Khandelwal
Journal:  Indian J Med Res       Date:  2017-11       Impact factor: 2.375

4.  The Islanding effect - a special method of percutaneous peritumor ethanol injection for hepatocellular carcinoma: 15-year follow-up outcome.

Authors:  Ze-Wu Meng; Xin-Ran Cai; Chang-Zhao Lin; Yan-Ling Chen; Song Liu
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.